Your session is about to expire
← Back to Search
Treatment for Human Immunodeficiency Virus Infection (Rollover Trial)
Phase 2
Waitlist Available
Led By Gary Blick, M.D.
Research Sponsored by VIRxSYS Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
Rollover Trial Summary
This trial is studying the long-term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells in people with HIV.
Rollover Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To evaluate the change between main study baseline CD4 counts and Month 9 post reinfusion
To evaluate the change in log10 HIV-1 RNA level
Helper-Inducer T-Lymphocyte
Secondary outcome measures
Changes in immune function as determined by ICS and TCR vβ Repertoire profile.
Find a Location
Who is running the clinical trial?
VIRxSYS CorporationLead Sponsor
1 Previous Clinical Trials
60 Total Patients Enrolled
Gary Blick, M.D.Principal InvestigatorCIRCLE Medical, LLC
Tessio E Rebello, PhDStudy DirectorVIRxSYS Corporation
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an ongoing enrollment period for this experiment?
"The records on clinicaltrials.gov demonstrate that this research is no longer enrolling participants, as its most recent update was in June of 2011. Since then, 485 other studies have opened up opportunities for patients to participate in a medical trial."
Answered by AI
To what extent can this therapy be hazardous to individuals?
"Our team at Power has determined that the safety of this therapy is rated a 2 due to its Phase 2 status, which implies there are some data points backing up its security but no studies in support of effectiveness."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger